{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T07:28:39Z","timestamp":1787383719189,"version":"build-2736575974"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Adult-onset Still\u2019s disease (AOSD) is a systemic autoinflammatory disorder, and macrophage activation syndrome is a life-threatening hyperinflammatory complication. Interleukin-1 and interleukin-6 inhibitors have improved outcomes in refractory AOSD, but optimal management of macrophage activation syndrome, particularly when it develops during biologic therapy, remains uncertain. We report a case of a 49-year-old woman with articular-predominant AOSD who developed fulminant macrophage activation syndrome while receiving high-dose glucocorticoids, tacrolimus, and the interleukin-6 receptor inhibitor tocilizumab. At the onset of macrophage activation syndrome, she had persistent fever, cytopenia, hyperferritinemia, and liver dysfunction, and bone marrow examination revealed haemophagocytosis. Macrophage activation syndrome persisted despite two courses of intravenous methylprednisolone pulse therapy and continuation of tocilizumab. Tocilizumab was discontinued, and treatment was switched to the oral Janus kinase 1\/2 inhibitor baricitinib in combination with glucocorticoids and tacrolimus. After this change, the patient experienced rapid defervescence, marked improvement in blood counts and ferritin levels, and sustained control of articular and systemic disease activity. Glucocorticoids were successfully tapered without relapse, and the patient remained in remission for more than 2 years without serious infections. To contextualise this case, we reviewed published reports on Janus kinase inhibition in AOSD, including cases complicated by macrophage activation syndrome. Multi-cytokine blockade through Janus kinase 1\/2 inhibition, targeting overlapping interleukin-6, interferon-gamma, and granulocyte\u2013macrophage colony-stimulating factor pathways, may simultaneously suppress macrophage activation and systemic inflammation. This case highlights the potential of baricitinib as a therapeutic option for refractory AOSD-associated macrophage activation syndrome during interleukin-6 inhibition.<\/jats:p>","DOI":"10.1093\/mrcr\/rxag072","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T11:58:34Z","timestamp":1783511914000},"source":"Crossref","is-referenced-by-count":1,"title":["Successful salvage treatment with baricitinib for macrophage activation syndrome complicating adult-onset Still\u2019s disease during interleukin-6 inhibition: A case report and literature review"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1604-5249","authenticated-orcid":false,"given":"Kazuma","family":"Nishisaka","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine , Kobe, Hyogo ,","place":["Japan"]},{"name":"Department of Intensive Care Medicine, Hyogo Prefectural Amagasaki General Medical Center , Amagasaki, Hyogo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6065-8486","authenticated-orcid":false,"given":"Yo","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine , Kobe, Hyogo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4668-1718","authenticated-orcid":false,"given":"Iku","family":"Shirasugi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine , Kobe, Hyogo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8090-6755","authenticated-orcid":false,"given":"Hirotaka","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine , Kobe, Hyogo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0873-5728","authenticated-orcid":false,"given":"Takaichi","family":"Okano","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine , Kobe, Hyogo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5100-9166","authenticated-orcid":false,"given":"Keisuke","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine , Kobe, Hyogo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7193-341X","authenticated-orcid":false,"given":"Sho","family":"Sendo","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine , Kobe, Hyogo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7606-3743","authenticated-orcid":false,"given":"Jun","family":"Saegusa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine , Kobe, Hyogo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,12]]},"reference":[{"key":"2026080709512125800_ref1","first-page":"424","article-title":"Preliminary criteria for classification of adult Still's disease","volume":"19","author":"Yamaguchi","year":"1992","journal-title":"J Rheumatol"},{"key":"2026080709512125800_ref2","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/00005792-200205000-00003","article-title":"Proposal for a new set of classification criteria for adult-onset still disease","volume":"81","author":"Fautrel","year":"2002","journal-title":"Medicine (Baltimore)"},{"key":"2026080709512125800_ref3","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.semarthrit.2017.07.005","article-title":"Validation of the Fautrel classification criteria for adult-onset Still's disease","volume":"47","author":"Lebrun","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2026080709512125800_ref4","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.autrev.2014.01.058","article-title":"Adult-onset Still's disease","volume":"13","author":"Gerfaud-Valentin","year":"2014","journal-title":"Autoimmun Rev"},{"key":"2026080709512125800_ref5","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.3899\/jrheum.111549","article-title":"Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study","volume":"39","author":"Nordstr\u00f6m","year":"2012","journal-title":"J Rheumatol"},{"key":"2026080709512125800_ref6","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1136\/annrheumdis-2018-213920","article-title":"Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial","volume":"77","author":"Kaneko","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2026080709512125800_ref7","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/art.43052","article-title":"Macrophage activation syndrome","volume":"77","author":"Nigrovic","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"2026080709512125800_ref8","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/annrheumdis-2015-208982","article-title":"2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism\/American College of Rheumatology\/Paediatric Rheumatology International Trials Organisation collaborative initiative","volume":"75","author":"Ravelli","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2026080709512125800_ref9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00296-018-4114-1","article-title":"Are the 2016 EULAR\/ACR\/PRINTO classification criteria for macrophage activation syndrome applicable to patients with adult-onset Still\u2019s disease?","volume":"39","author":"Tada","year":"2019","journal-title":"Rheumatol Int"},{"key":"2026080709512125800_ref10","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/blood.2024026139","article-title":"Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in China","volume":"146","author":"Zhou","year":"2025","journal-title":"Blood"},{"key":"2026080709512125800_ref11","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1136\/ard-2024-225851","article-title":"EULAR\/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease","volume":"83","author":"Fautrel","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026080709512125800_ref12","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/rheumatology\/key414","article-title":"Treatment of refractory adult onset Still's disease with combination anakinra and baricitinib therapy","volume":"58","author":"Ladhari","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2026080709512125800_ref13","doi-asserted-by":"crossref","first-page":"e001246","DOI":"10.1136\/rmdopen-2020-001246","article-title":"Mixed results with baricitinib in biological-resistant adult-onset Still's disease and undifferentiated systemic autoinflammatory disease","volume":"6","author":"Kacar","year":"2020","journal-title":"RMD Open"},{"key":"2026080709512125800_ref14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40268-023-00417-7","article-title":"Efficacy of baricitinib in patients with refractory adult-onset Still's disease","volume":"23","author":"Sun","year":"2023","journal-title":"Drugs R D"},{"key":"2026080709512125800_ref15","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s10067-025-07352-9","article-title":"Salvage treatment of AOSD-associated macrophage activation syndrome with bariticinib following conventional immunosuppressive therapy","volume":"44","author":"Xu","year":"2025","journal-title":"Clin Rheumatol"},{"key":"2026080709512125800_ref16","doi-asserted-by":"crossref","first-page":"217","DOI":"10.5152\/eurjrheum.2022.21064","article-title":"Ruxolitinib for refractory macrophage activation syndrome complicating adult-onset Still's disease","volume":"9","author":"Levy","year":"2022","journal-title":"Eur J Rheumatol"},{"key":"2026080709512125800_ref17","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1093\/rheumatology\/keac694","article-title":"Ruxolitinib rescued the macrophage activation syndrome in adult-onset Still's disease with delayed hypersensitivity reaction to tocilizumab","volume":"62","author":"Fu","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2026080709512125800_ref18","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood.2024024362","article-title":"Ruxolitinib targets JAK-STAT signaling to modulate neutrophil activation in refractory macrophage activation syndrome","volume":"146","author":"Ma","year":"2025","journal-title":"Blood."},{"key":"2026080709512125800_ref19","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1136\/annrheumdis-2019-216699","article-title":"Tofacitinib in refractory adult-onset Still's disease: 14 cases from a single Centre in China","volume":"79","author":"Hu","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2026080709512125800_ref20","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1080\/03009742.2020.1729405","article-title":"Tofacitinib-induced remission in refractory adult-onset Still\u2019s disease complicated by macrophage activation syndrome","volume":"49","author":"Honda","year":"2020","journal-title":"Scand J Rheumatol"},{"key":"2026080709512125800_ref21","first-page":"e84770","article-title":"Tofacitinib in the treatment of refractory adult-onset Still's disease co-diagnosed with celiac disease: a case report","volume":"17","author":"Alhayali","year":"2025","journal-title":"Cureus"},{"key":"2026080709512125800_ref22","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1007\/s10067-025-07465-1","article-title":"Tofacitinib as a possible treatment in macrophage activation syndrome: a pilot single-center study in China","volume":"44","author":"Xie","year":"2025","journal-title":"Clin Rheumatol"},{"key":"2026080709512125800_ref23","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s40268-024-00487-1","article-title":"A case report of JAK inhibitors therapy for adult-onset Still's disease with persistent pruritic lesions","volume":"24","author":"Tang","year":"2024","journal-title":"Drugs R D"},{"key":"2026080709512125800_ref24","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41584-023-01065-6","article-title":"Recent advances and evolving concepts in Still's disease","volume":"20","author":"Ruscitti","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"2026080709512125800_ref25","doi-asserted-by":"crossref","first-page":"105771","DOI":"10.1016\/j.jbspin.2024.105771","article-title":"Musculoskeletal ultrasound findings in adult-onset Still's disease: a case series","volume":"91","author":"Yamamoto","year":"2024","journal-title":"Joint Bone Spine"},{"key":"2026080709512125800_ref26","first-page":"tr8","article-title":"The Jak-STAT pathway stimulated by interferon gamma","volume":"2004","author":"Horvath","year":"2004","journal-title":"Sci STKE"},{"key":"2026080709512125800_ref27","doi-asserted-by":"crossref","first-page":"1389710","DOI":"10.3389\/fimmu.2024.1389710","article-title":"Heterogeneity of macrophage activation syndrome and treatment progression","volume":"15","author":"Dong","year":"2024","journal-title":"Front Immunol"},{"key":"2026080709512125800_ref28","doi-asserted-by":"crossref","first-page":"932608","DOI":"10.3389\/fonc.2022.932608","article-title":"A review of granulocyte colony-stimulating factor receptor signaling and regulation with implications for cancer","volume":"12","author":"Park","year":"2022","journal-title":"Front Oncol"},{"key":"2026080709512125800_ref29","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1074\/jbc.273.2.1058","article-title":"Granulocyte-macrophage colony-stimulating factor-activated signaling pathways in human neutrophils: selective activation of Jak2, Stat3, and Stat5b","volume":"273","author":"Al-Shami","year":"1998","journal-title":"J Biol Chem"},{"key":"2026080709512125800_ref30","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1136\/ard-2022-223739","article-title":"Efficacy and safety of emapalumab in macrophage activation syndrome","volume":"82","author":"De Benedetti","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026080709512125800_ref31","doi-asserted-by":"crossref","first-page":"1604648","DOI":"10.3389\/fimmu.2025.1604648","article-title":"Efficacy and safety of ruxolitinib in adult patients with refractory rheumatic disease-associated macrophage activation syndrome","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"2026080709512125800_ref32","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s12276-024-01182-6","article-title":"Immunopathology of and potential therapeutics for secondary hemophagocytic lymphohistiocytosis\/macrophage activation syndrome: a translational perspective","volume":"56","author":"Nguyen","year":"2024","journal-title":"Exp Mol Med"},{"key":"2026080709512125800_ref33","volume-title":"Report on the Deliberation Results: Olumiant Tablets 2 mg and 4 mg","author":"Pharmaceuticals and Medical Devices Agency","year":"2017"},{"key":"2026080709512125800_ref34","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/rheumatology\/kead448","article-title":"Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases","volume":"63","author":"Taylor","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2026080709512125800_ref35","doi-asserted-by":"crossref","first-page":"614704","DOI":"10.3389\/fimmu.2021.614704","article-title":"Use of the JAK inhibitor ruxolitinib in the treatment of hemophagocytic lymphohistiocytosis","volume":"12","author":"Keenan","year":"2021","journal-title":"Front Immunol"},{"key":"2026080709512125800_ref36","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12865-020-00365-w","article-title":"JAK inhibitors impair GM-CSF-mediated signaling in innate immune cells","volume":"21","author":"Fujita","year":"2020","journal-title":"BMC Immunol"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxag072\/68760794\/rxag072.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/10\/2\/rxag072\/68760794\/rxag072.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/10\/2\/rxag072\/68760794\/rxag072.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T13:51:30Z","timestamp":1786110690000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/doi\/10.1093\/mrcr\/rxag072\/8732751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6,29]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxag072","relation":{},"ISSN":["2472-5625"],"issn-type":[{"value":"2472-5625","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"rxag072"}}